- POAI
recently announced the sale of 10 FDA-approved, CE-marked STREAMWAY
Systems
- STREAMWAY
Systems are the first truly continuous, direct-to drain fluid-disposal
solutions designed specifically for medical applications
- The
announcement is another positive indication that POAI subsidiary
Skyline Medical offers tremendous qualitative, long-term potential
In a significant announcement that bodes well for the
company, Predictive Oncology Inc. (NASDAQ: POAI) announced that
its Skyline Medical Division, producer of the STREAMWAY(R) System, has
completed the sale of 10 systems to a major New York hospital (http://ibn.fm/dXHwp). The sale
exceeds POAI’s largest single-hospital sale to date, and it is anticipated that
the systems collectively will handle 6,000 procedures every year.
The revolutionary FDA-approved, CE-marked STREAMWAY System
is the first truly continuous, direct-to drain, fluid-disposal system designed
specifically for medical applications such as radiology, endoscopy, surgery,
urology and cystoscopy procedures.
STREAMWAY is transforming the way healthcare facilities
process and handle potentially infectious waste. The innovative system connects
directly to a facility’s plumbing system in order to automate the collection,
measurement and disposal of waste fluids. This proprietary approach minimizes
human intervention, creates a safer system, and provides improved compliancy
with Occupational Safety and Health Administration (OSHA) and other regulatory
agency safety guidelines (http://ibn.fm/O0FzQ).
Moreover, because the STREAMWAY system doesn’t require
canisters and evacuated bottles for collection purposes, it eliminates
approximately 50 million potentially disease-infected canisters that wind up in
landfills around the country. In addition to the positive environmental impact,
the system also reduces overhead costs.
For Predictive Oncology, this announcement represents a
significant financial milestone. As POAI’s largest single-hospital transaction
ever, the sale indicates the credibility and trust the STREAMWAY System is
building within the industry. In addition, the sale is another positive
indication that Skyline Medical, a POAI subsidiary, provides tremendous
qualitative, long-term potential as it continues to focus on and develop
innovative and revolutionary technology and alternatives. Through its STREAMWAY
System, Skyline has achieved sales in five of the seven continents through both
direct sales and distributor partners.
Predictive Oncology operates in two business areas: first,
applying artificial intelligence to personalized medicine and drug discovery to
provide personalized medicine solutions for patients and clinicians as well as
clients in the pharmaceutical, diagnostic, and biotech industries; and second,
production of the STREAMWAY System through Skyline Medical.
For more information, visit the company’s website at www.Predictive-Oncology.com
NOTE TO INVESTORS: The latest news and updates
relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI
About MissionIR
MissionIR is
primarily focused on strategic communications. We have executed countless
communications programs to address the needs of companies ranging from
start-ups to established industry leaders, gaining valuable experience and the
expertise necessary to determine the most effective strategy for any given
situation.
For more information, visit www.MissionIR.com
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
